Benefits of adding drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis

JAMA

Volumn 292, Issue 4, 2004, Pages 470-484

  Delbaldo, Catherine ^a   Michiels, Stefan ^a   Syz, Nathalie ^a   Soria, Jean Charles ^a   Le Chevalier, Thierry ^a   Pignon, Jean Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; TEGAFUR; TENIPOSIDE; TIRAPAZAMINE; VINCRISTINE; VINDESINE;

ADVANCED CANCER; ANEMIA; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EMBASE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; REVIEW; SURVIVAL; THROMBOCYTOPENIA; VOMITING; ARTICLE; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3242803674     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.4.470     Document Type: Review

References (96)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin. 2002;52:23-47.
2. Ihde DC, Minna JD. Non-small cell lung cancer, part I: biology, diagnosis, and staging. Curr Probl Cancer. 1991;15:61-104.
3. Juretic A, Sobat H, Samija M. Combined modality therapy of non-small cell lung cancers. Ann Oncol. 1999;10(suppl 6):93-98.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909.
5. Natale RB. Overview of current and future chemotherapeutic agents in non-small cell lung cancer. Semin Oncol. 1997;24(2 suppl 7):S7-S29.
6. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet. 1993;342:19-21.
7. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest. 1994;106:861-865.
8. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol. 1993;11:1866-1872.
9. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J. Clin Oncol. 1997;15:2996-3018.
10. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618-1626.
11. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434-1441.
12. Bunn PA Jr. Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol. 2002;20:3565-3567.
13. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer. 1998;82:116-126.
14. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001;19:1734-1742.
15. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4:1087-1100.
16. Waters JS, O'Brien ME. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of the National Institute of Clinical Excellence (NICE). Br J Cancer. 2002;87:481-490.
17. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002;13:1539-1549.
18. Soria JC, Le Chevalier T. Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol. 2002;13:1515-1517.
19. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
20. Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med. 1987;6:11-29.
21. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993;341:418-422.
22. Elliott JA, Ahmedzai S, Hole D, et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer. 1984;20:1025-1032.
23. Einhorn LH, Loehrer PJ, Williams SD, et al. Randomized prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol. 1986;4:1037-1043.
24. Rosso R, Salvati F, Ardizzoni A, et al, for the Italian Lung Cancer Task Force. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: results of a prospective randomized FONICAP trial. Cancer. 1990; 66:130-134.
25. Splinter TA, Sahmoud T, Festen J, et al. Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14:127-134.
26. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994;12:360-367.
27. Soria JC, Douillard JY, Pujol JL, et al. Prognostic analysis of survival in the European trial comparing navelbine (Nvb) vs navelbine cisplatine (Nvb-P) vs vindesine cisplatine (VDS-P). Proc Am Soc Clin Oncol. 1999;18:491a.
28. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 1994;5:37-42.
29. Gil Deza G, Balbiani L, Coppola F, et al. Phase III study of navelbine (NVB) vs NVB plus cisplatin in non small cell lung cancer (NSCLC) Stage IIIB or IV. Proc Am Soc Clin Oncol. 1996;15:394.
30. Lorusso V, Pezzella G, Catino A, et al. Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alone. Int J Oncol. 1995; 6:65-68.
31. Negoro S, Masuda N, Takada Y, et al. Randomized phase III trial of irinotecan combined with cisplatine for advanced non-small-cell lung cancer. Br J Cancer. 2003;88:335-341.
32. Berardi R, Porfiri E, Masidda B, et al. Gemcitabine (GEM) and cisplatin (PL) versus gemcitabine alone in stage IV non small cell lung cancer (NSCLC): preliminary results of a randomized multicenter phase III study. Proc Am Soc Clin Oncol. 2001;20:347a.
33. Georgoulias G, Pallis AG, Kourousis C, et al. Docetaxel versus docetaxel/cisplatin in patients with advanced non-small cell lung cancer: preliminary analysis of a multicenter, randomized phase III study. Clin Lung Cancer. 2003;4:288-293.
34. Luedke DW, Einhorn L, Omura GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990;8:886-891.
35. Gorospe A, Crista-Luna G, Li R, et al. Initial comparative study on the efficacy of single agent gemcitabine versus combination gemcitabine and cisplatine in Filipino patients with advanced non-small cell lung cancer. Lung Cancer. 2000;29(suppl 1):70.
36. Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N. Prolonged administration of oral etoposide alone of with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial. Lung Cancer. 1997;18:179-188.
37. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol. 2002;29: 50-54.
38. Kawahara M, Furuse K, Kodama N, et al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer. 1991; 68:714-719.
39. Tsuruta M, Furuse K, Arai R, et al. A randomized study of cisplatin (C) versus cisplatin (C) plus vindesine (V) in non-small cell carcinoma of the lung (NSCLC). Lung Cancer. 1986;2:113.
40. Crino L, Tonato M, Darwish S, et al. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol. 1990;26:52-56.
41. Klastersky J, Sculier JP, Bureau G, et al, for the Lung Cancer Working Party, Belgium. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol. 1989;7:1087-1092.
42. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993;11:873-878.
43. Rivero S, Balbiani L, Bonicatto S, et al. Vinorelbine (VNB) with (A) or without (B) ifosfamide (IFX) in nonoperable non small cell lung cancer (NSCLC): efficacy and tolerance in a phase III study preliminary report. Proc Am Soc Clin Oncol. 1999;18:2010.
44. Denkmayr M, Orthman M. Cisplatin (DDP) versus DDP+mitoxantrone (MXO) for adenocarcinoma of the lung (ACL). Lung Cancer. 1991;7(suppl):130.
45. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:3390-3399.
46. Sandler AB, Nemunaltis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18: 122-130.
47. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:2529-2536.
48. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomised trial. J Natl Cancer Inst. 2003;95:362-372.
49. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16:2459-2465.
50. von Pawel J, von Roemeling R, Gatzemeier U, et al, for the Cisplatin and Tirapazamine in Subjects With Advanced Previously Untreated Non-Small-Cell Lung Tumors Group. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J Clin Oncol. 2000;18:1351-1359.
51. Jensen N, Hansen O, Jensen A, Rose C. Carboplatin versus carboplatin plus docetaxel in first line treatment of advanced non-small cell lung cancer (NSCLC): quality of life, costs and health resources. Proc Am Soc Clin Oncol. 2002;21:322a.
52. Paccagnella A, Favaretto A, Brandes A, et al. Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma: a phase II randomized study with cisplatin and etoposide as the control arm. Cancer. 1990; 65:2631-2634.
53. Masutani M, Akusawa H, Kadota A, et al. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology. 1996;1:49-54.
54. Hiraki S, Ohnoshi T, Ueoka H, Horiguchi T, Kodani T, Kimura I. Randomized study comparing cisplatin (CDDP) and vindesine (VDS) combination (PV) and CDDP, VDS and ifosfamide (IFX) combination (PVI) in non-small cell lung cancer (NSCLC). Lung Cancer. 1991;7(suppl):111.
55. Kodani T, Ueoka H, Kiura K, et al. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer. 2002;36: 313-319.
56. Kosmidis P, Mylonakis N, Skarlos DC, et al. A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. Ann Oncol. 1994;5:159-162.
57. Erkisi M, Doran F, Burgut R, Kocabas A. A randomised trial of two cisplatin-containing chemotherapy regimens in patients with stage III-B and IV non-small cell lung cancer. Lung Cancer. 1995;12: 237-246.
58. Souquet P, Tan EH, Rodrigues Pereira J, et al. GLOB 1: a prospective randomized clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol. 2002;13:1853-1861.
59. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989;7: 1602-1613.
60. Fukuoka M, Masuda N, Furuse K, et al. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol. 1991;9:606-613.
61. Shinkai T, Eguchi K, Sasaki Y, et al. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 1991;27:571-575.
62. Negoro S, Fukuoka M, Furuse K, Kawahara M. Cisplatin (P) and vindesine (V) vs cisplatin, vindesine and mitomycin (M) vs cisplatin and etoposide (E) alternating with vindesine and mitomycin in the treatment of advanced non-small cell lung cancer (NSCLC). Lung Cancer. 1988;4(suppl):A126.
63. Areco A, Chiesa G, Morero J, et al. A randomized study of cisplatin (CDDP), etoposide (VP16) with or without mitomycin (Mito C) in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol. 1989; 8:240.
64. Mencoboni M, Lerza R, Castello G, et al. Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer. Anticancer Res. 1997;17:2795-2798.
65. Laack E, Dierlamm T, Dickgreber N, et al. Randomized phase III study of gemcitabine+vinorelbine (GV) versus gemcitabine+vinorelbine+cisplatin (GVP) in metastatic non-small cell lung cancer (NSCLC). Ann Oncol. 2002;13(suppl 5):128.
66. Greco FA, Gray J, Thompson D, et al. Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network Trial. Cancer. 2002;95:1279-1285.
67. Dhingra HM, Valdivieso M, Carr DT, et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol. 1985; 3:176-183.
68. Hoffman PC, Bitran J, Golomb H, Albain KS, Skosey C. Do high-dose cisplatin regimens add to the therapy of metastatic non-small cell lung cancer (NSCLC)? Proc Am Soc Clin Oncol. 1985;4:185.
69. Hainsworth JD, Johnson DH, Hande KR, Greco FA. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cisplatin-based chemotherapy regimens. Am J Clin Oncol. 1989;12:345-349.
70. Richards F, Perry DJ, Goutsou M, et al. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. Cancer. 1991;67:2974-2979.
71. Bando H, Kinoshita S, Atagi S, et al. Randomized study of cisplatin and doxorubicin with or without vincristine in non-small cell lung cancer [in Japanese]. Gan To Kagaku Ryoho. 1986;13:2094-2099.
72. Breau J, Morère J, Israel L. Chemotherapy with or without lonidamine for induction therapy in squamous cell carcinoma of the lung: a randomized study comparing cisplatinium-bleomycin or cisplatiniumbleomycin-VP 16213 (+-Ionidamine). Proc Am Soc Clin Oncol. 1988;7:212.
73. Shah S, Harvey H, Lipton L, et al. A randomized study of vinblastine and cisplatine (VBL+CDDP) vs vinblastine, cisplatine and 5 FU five days continuous infusion in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 1988;7:211.
74. Gralla R, Lee J, Kris M, et al. Multicenter, randomized trials comparing the combination of edatrexate, mitomycin and vinblastine (EMV) with mitomycin and vinblastine (MV) in 673 patients with stage III and IV non-small cell lung cancer. Proc Am Soc Clin Oncol. 1994;13:347.
75. Nakabayashi T, Yasuda S, Miyomato H, Abe S, Ohsaki Y. Randomized study with various combination of cisplatinum (CDDP), mitomycin C (MMC), peplomycin (PEP) and ftoraftur (FT) for the treatment of non-small cell lung cancer. Lung Cancer. 1986;2:124.
76. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000;18:1451-1457.
77. Alberola V, Camps C, Provencia M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase II randomized trial. J Clin Oncol. 2003;21:3207-3213.
78. Hussein A, Birch R, Waller J, et al. Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2000;19:504a.
79. Pérol M, Lena H, Thomas P, et al. Phase III randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small cell lung cancer: GFPC 97.01 study. Ann Oncol. 2002;13:742-747.
80. Edelman MJ, Heather G, Mullius B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol. 2001;48:141-144.
81. Zoli W, Ricotti L, Dal Susino M, et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer. 1999;81:609-615.
82. Crino L, Cappuzzo F. Present and future treatment of advanced non-small cell lung cancer. Semin Oncol. 2002;29(3 suppl 9):9-16.
83. Bunn PA, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000; 117(4 suppl 1):138S-143S.
84. Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol. 2001;12:1667-1670.
85. Sweeny CJ, Zhu J, Sandler AB, et al. Outcome of patients with performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial of patients with metastatic non-small cell lung carcinoma. Cancer. 2001;92:2639-2647.
86. Lilenbaum RC, Herndon J, List M, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALBG randomized trial of efficacy, quality of life (QQL) and cost-effectiveness. Proc Am Soc Clin Oncol. 2002; 21:2.
87. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol. 2003;22:639.
88. Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer. 2001;34:S95-S101.
89. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004;22:759-761.
90. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004;22:785-794.
91. Bissett D, von Pawel J, Mercier R, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:296a.
92. Gatzemeier U, Groth G, Hirsh V, et al. Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomised phase II study. Proc Am Soc Clin Oncol. 2002;21:297a.
93. Baggstrom MQ, Socinski MA, Hensing TA, Poole C. Addressing the optimal number of cytotoxic agents in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol. 2003;22:624.
94. Baggstrom MQ, Socinski MA, Hensing TA, Poole C. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol. 2002;21:306a.
95. Williamson PR, Marson AG, Tudur C, et al. Individual patient data meta-analysis of randomized antiepileptic drug monotherapy trials. J Eval Clin Pract. 2000;6:205-214.
96. Michiels S, Piedbois P, Syz N, et al. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care. In press.